Introduction
Between 1985 and 2001, the use of definitive chemoradiotherapy (CRT) for the initial management of locally advanced oropharyngeal carcinoma increased from 15% of cases to 29%, according to data obtained from the National Cancer Institute Database. 1 The trend toward greater emphasis on organ preservation is occurring largely in response to the results of several randomized trials that have demonstrated better survival and local control in patients who were treated with CRT compared with those treated with radiotherapy alone, as well as a desire to lessen the morbidity traditionally associated with open surgical approaches followed by adjuvant radiotherapy. 2, 3 A meta-analysis by Parsons et al found that patients with oropharyngeal carcinoma experienced similar local control and overall survival rates regardless of whether they were treated initially with surgery or radiotherapy, although they did experience significantly more complications with the former. 4 As a result, definitive CRT was adopted as the standard treatment at many centers.
Moreover, data have emerged showing that patients with human papillomavirus (HPV)-negative oropharyngeal cancer experience significantly worse outcomes than do their HPV-positive counterparts. [5] [6] [7] [8] [9] Studies demonstrating the relative treatment resistance of HPV-negative cancer have raised the question of whether Rash, Daly, DuRbin-Johnson, Vaughan, Chen a more aggressive approach that incorporates primary surgery followed by radiotherapy, with or without chemotherapy, might lead to better outcomes than those associated with CRT alone. In this article, we describe our study that compared the clinical outcomes of patients with HPV-negative oropharyngeal cancer who were treated with one or the other of these approaches.
Patients and methods
We retrospectively reviewed the medical records of 162 consecutively presenting patients with stage III or IV nonmetastatic squamous cell carcinoma of the oropharynx who had been treated with radiotherapy at our institution from July 2006 through December 2012. From this group, we identified 51 patients-38 men and 13 women, aged 46 to 74 years (median: 57)-who had had HPV-negative cancer, as determined by absent or weak immunohistochemical expression of p16. The 2009 AJCC (American Joint Committee on Cancer) classification was used for staging. 10 At baseline, Karnofsky Performance Status Scale scores were 70 or greater for all patients. Of the 51 patients, 45 (88%) reported a history of tobacco use (median intensity: 40 pack-years), and 39 patients (76%) reported moderate to heavy alcohol use (table) .
Patients were divided into two groups based on the type of treatment they received. Some 22 patients had been treated with primary surgery followed by postoperative radiotherapy (S/RT group), and 29 were treated with definitive CRT alone (CRT group). There were no statistically significant differences between the two cohorts in sex, median age, cancer stage, intensity of smoking history, or alcohol use (p > 0.05 for all).
Cancer staging. In the S/RT group, the T categories were fairly evenly distributed, but in the CRT group, T4 was dominant; N2b was the most common nodal status in both groups. Almost all patients in both groups had stage IV cancer (table) .
Treatment. Decisions regarding the treatment of oropharyngeal cancer were typically made in a multidisciplinary setting at a weekly tumor conference, where cases were presented and all relevant material, including imaging and pathologic findings, were prospectively reviewed. In general, the criteria for operability depended on patient-related factors such as performance status and underlying comorbidities, while keeping in mind the functional and cosmetic considerations at the surgeon's discretion.
Surgery. Gross total tumor resection with microscopic negative margins was achieved in 15 of the 22 S/RT patients (68%) of patients. Margins were positive or close in 5 (23%) and 2 (9%) patients, respectively. The surgical approach typically consisted of an open mandibulotomy and composite resection with attention to functional and cosmetic considerations. Free-flap microvascular reconstruction was used to close the surgical defects. Transoral approaches with laser microsurgery or robot assistance were performed on 6 patients (27%) at the discretion and expertise of the treating surgeon. Ipsilateral neck dissection was performed in all surgical cases, with consideration given to contralateral neck dissection based on the extent and location of the primary tumor.
TreaTmenT ouTcomes in HPV-negaTiVe oroPHaryngeal cancer: surgery Plus radioTHeraPy Vs. definiTiVe cHemoradioTHeraPy On pathologic evaluation, 8 patients (36%) had bilateral neck disease. In addition, 15 patients (68%) had extracapsular invasion, 8 had perineural invasion, and 6 (27%) had lymphovascular space invasion.
Adjuvant therapy. No definite policy regarding adjuvant therapy existed, but patients were generally referred for postoperative radiotherapy in the presence of high-risk features such as positive margins, multiple lymph node involvement, extracapsular extension, perineural or lymphovascular space invasion, and bone invasion, or when there was uncertainty about the adequacy of the excision based on intraoperative and pathologic findings.
Radiotherapy. Intensity-modulated radiotherapy (IMRT) was planned with either the Pinnacle 3 treatment planning system (Philips; Amsterdam, The Netherlands) or the TomoTherapy system (Accuray; Madison, Wis.) to deliver 6-MV photons. At simulation and before daily treatment, the head, neck, and shoulders were immobilized with a perforated thermoplastic mask supported by a Timo cushion (S type; Med-Tec; Orange City, Iowa) mounted on a carbon fiberboard that allowed patient positioning to be indexed. At the time of simulation, the isocenter was placed approximately at the center of the gross tumor volume. Computed tomography data were then transferred to a contouring workstation where delineation of target and normal tissue structures was performed.
For patients treated with definitive IMRT, the gross tumor volume was defined as the gross extent of tumor as determined by preoperative imaging and physical examination, including endoscopy. A grossly positive lymph node was defined as any node larger than 1 cm or one that had a necrotic center.
The high-risk clinical target volume was defined as the gross tumor volume plus a margin of at least 0.5 cm to account for microscopic disease spread. For patients treated with IMRT postoperatively, the high-risk clinical target volume was defined as the surgical tumor bed at risk for harboring microscopic residual disease. For both definitively and postoperatively treated patients, the moderate-risk clinical target volume generally included the prophylactically treated cervical and supraclavicular neck. In some additional cases, a low-risk clinical target volume was created to designate an area at lowest risk within the prophylactically treated low neck.
The planning target volume (PTV) contained an automated 0.3-to 0.5-cm circumferential expansion of the clinical target volume surfaces to account for patient setup error to create PTV-1, PTV-2, and PTV-3, if necessary, to correspond to high-, intermediate-, and low-risk targets.
For patients receiving definitive IMRT, treatment plans were designed to provide a dose of 66 to 70 Gy to 95% or more of PTV-1 and 60 to 63 Gy to 95% or more of PTV-2 while sparing neighboring critical structures. For patients treated postoperatively, plans were designed to deliver a dose of 60 to 66 Gy to at least 95% of PTV-1 and 54 to 56 Gy to PTV-2. The prescribed dose to PTV-3 was 50 to 56 Gy. For patients treated with primary CRT, doses to PTV-1 ranged from 40 to 70 Gy (median: 70). For patients treated with postoperative radiotherapy after surgery, the doses to PTV-1 ranged from 60 to 70 Gy (median: 66).
Chemotherapy. Concurrent chemotherapy was administered with postoperative radiotherapy in 13 of the 22 S/RT patients (59%). The most commonly prescribed regimen used with radiotherapy (either definitive or postoperative) was cisplatin, which was administered either at 50 mg/m 2 on weeks 1, 2, 4, and 5 for four cycles or at 100 mg/m 2 on weeks 1, 3, and 6 for three cycles. Other chemotherapeutic regimens included cisplatin with cetuximab, carboplatin with paclitaxel, and docetaxol alone.
Outcomes measures. Clinical outcomes-including patterns of treatment failure, time to recurrence, progression-free survival, and overall survival-were compared in the two groups. Local control was judged to have been attained if there was no evidence of tumor at the primary site based on clinical and radiologic findings at follow-up. Regional failure was recorded separately if there was evidence of a cervical or supraclavicular mass distinct from the tumor at the primary site.
Patients who had persistent disease, either clinically or radiologically, after definitive radiotherapy were referred for consideration of salvage neck dissection. Failure was determined only when patients exhibited pathologic evidence of residual disease.
Statistical analysis. The chi-square test for independence was used to determine if statistically significant differences existed in initial characteristics for the two cohorts. Actuarial estimates for progression-free survival and overall survival were calculated according to the Kaplan-Meier method, with comparisons between groups made with log-rank tests. Multivariate analyses to assess the effects of treatment and risk factors on time-to-event outcomes were performed with Cox proportional hazards models. All tests were two-tailed, with a p value of <0.05 considered statistically significant.
Ethical considerations. Institutional Review Board approval was obtained for the study protocol.
Results
The crude rate of locoregional recurrence for all patients was 29% (15/51); rates were 36% (8/22) in the S/ RT group and 24% (7/29) in the CRT group (p = 0.43). Distant metastases occurred in 14% (3/22) and 21% (6/29), respectively (p = 0.56); there was no significant difference in time to distant metastasis. At 2 years of follow-up, we found no significant differences between the S/RT group and the CRT group in progression-free survival (66 vs. 62%; p = 0.64) and overall survival (75 vs. 76%; p = 0.83) (figure). On univariate analysis, progression-free survival and overall survival were worst among patients with T4 tumors and those with bilateral neck disease, but neither difference was statistically significant. Similarly, the number of packyears of tobacco smoking (p = 0.76) and the intensity of alcohol use (p = 0.29) did not significantly impact local recurrence or survival. Nor did multivariate analysis find any differences in progression-free and overall survival in terms of tumor stage, smoking pack-years, and alcohol use.
Among the 15 patients who developed a locoregional recurrence, 7 (47%) had T4 disease; among those patients, 4 were treated with primary surgery and 3 were treated with definitive CRT. Of the 8 patients in the S/RT group who developed a locoregional recurrence, all (100%) had extracapsular extension, 4 (50%) had positive surgical margins, 5 (63%) had bilateral neck disease, 5 had lymphovascular space invasion, and 6 (75%) had perineural invasion on the initial pathology review.
Salvage surgery was performed on 5 of the 51 patients (10%) after definitive treatment; 2 of these patients were treated initially with primary surgery followed by concurrent CRT for high-risk features. Among these 5 patients, 3 were alive without disease at last follow-up (range: 20 to 50 mo).
All 5 patients (10%) who developed a second primary tumor had a tobacco history of 20 pack-years or more, and all had been treated with definitive CRT.
Discussion
Our study failed to demonstrate any differences between the S/RT group and the CRT group in any of the clinical outcomes we analyzed. Specifically, locoregional recurrence developed at equally high rates in the two cohorts, affirming the increasingly recognized belief that HPV-negative oropharyngeal cancer represents a treatment-resistant entity and a distinct therapeutic challenge.
Our findings are consistent with those reported in other surgery-vs.-CRT series in terms of demonstrating relatively poor outcomes for patients with HPV-negative oropharyngeal cancer. 5, 8, 9, 11 Unfortunately, comparisons among treatment modalities for oropharyngeal cancer have been limited, and only a few studies have evaluated differences based on HPV subtype. For instance, investigators in Basel, Switzerland, reviewed clinical outcomes and found that p16 positivity conferred a favorable survival advantage of similar magnitude for both surgically and nonsurgically treated patients with oropharyngeal cancer. 12 The practice of using HPV status to determine the type of treatment modality is controversial. Even so, it has been well established that regardless of the initial approach, patients with HPV-negative squamous cell carcinoma of the oropharynx have worse survival rates than do patients with HPV-positive disease. [5] [6] [7] [8] A metaanalysis of 30 trials that specifically evaluated HPV status in oropharyngeal cancer found that HPV-positivity in patients treated with a radiotherapy-based modality was associated with a 60% reduction in the risk of death. 12 The mechanism for this dramatic difference is not clear, but it is likely multifactorial and influenced by differences in molecular carcinogenesis, tumor oxygenation, and response to therapy.
Patients with HPV-negative cancer have also frequently reported higher rates of tobacco smoking and alcohol use than HPV-positive patients have. The presence of these risk factors increases the incidence of somatic mutations in p53, p16, retinoblastoma, and cyclin D1 expression, which might render tumors less sensitive to cytotoxic therapy. 13, 14 Preclinical studies have found that HPV-negative head and neck squamous cell carcinoma cell lines exhibit greater radioresistance than do HPV-positive cell lines. 15, 16 This effect might be mediated by increased epidermal growth factor receptor (EGFR) expres-
Figure. Graphs show no statistically significant differences between the S/RT group and the CRT group in terms of progression-free survival (A) and overall survival (B).
TreaTmenT ouTcomes in HPV-negaTiVe oroPHaryngeal cancer: surgery Plus radioTHeraPy Vs. definiTiVe cHemoradioTHeraPy sion, which has been associated with squamous cell carcinoma cell lines that respond poorly to radiotherapy. 17 It has been hypothesized that cells with greater EGFR expression repair radiotherapy-induced DNA damage more proficiently, which results in a greater risk of local recurrence.
Other preclinical work has characterized the HGF-MET pathway and its role in HPV-negative disease. By activating MEK and AKT, HGF-MET increases angiogenesis, cell migration, and stromal invasion. In addition, upregulation of AKT signaling might play a direct role in the radioresistance of HPV-negative head and neck cancer cell lines. 16 Host immune responses also have been implicated in the clearance of HPV-positive tumors, which is largely dependent on the presence of E6 and E7 viral oncoproteins that interfere with the function of p53 and retinoblastoma, respectively. In immunocompromised animal models, the radioresponse of animals who had an HPV-positive tumor was lower than that of animals who had an intact immune system. 18 Therefore, the relative radioresistance of HPV-negative tumor cells might be attributable in part to the absence of a virally mediated antigen-specific immune response.
Finally, it is possible that differences in medical and psychosocial comorbidities among HPV-positive and HPV-negative oropharyngeal cancer patients contribute to differences in treatment compliance and thus clinical outcomes. Efforts to improve outcomes may ultimately depend on escalating therapy by the addition of more aggressive chemotherapeutic regimens, targeted immunotherapy, or accelerated fractionation.
The desire to minimize patient morbidity while maintaining cure rates has driven most of the recent advances in the treatment of locally advanced oropharyngeal cancer. More studies similar to ours are needed to determine if more aggressive approaches, such as the addition of surgery to CRT, improves outcomes for patients with HPV-negative oropharyngeal cancer. This is particularly important because the functional impairment associated with both primary surgery and CRT has been well described, and the lasting effects of these treatments can significantly impact quality of life.
In their 2002 meta-analysis, Parsons et al found higher rates of severe or fatal complications among patients treated with primary surgery (23 to 32%) than in those treated with nonsurgical modalities (0.4 to 6%). 4 Since then, the addition of chemotherapy to radiotherapy has been shown to increase the risk of late toxicity, including soft-tissue fibrosis, dysphagia, xerostomia, and dental complications. 2, 3 However, efforts to compare quality-of-life outcomes between treatment modalities are limited by retrospective biases and subjective evaluation methods.
Gillespie et al suggested that outcomes were better in oropharyngeal cancer patients who were treated with CRT rather than with surgery and radiotherapy, notably regarding swallowing function as measured by a modified barium swallow study, as well as emotional and functional subscales of the M.D. Anderson Dysphagia Inventory. 19 In contrast, other investigators have not found any difference in quality of life between treatment groups. 20, 21 It must be recognized that most of the S/RT patients in our series were treated with open surgical approaches. Transoral robotic surgery (TORS) has emerged as a successful alternative to open surgical approaches for the resection of oropharyngeal carcinoma. Multiple series have demonstrated less morbidity with TORS than with open approaches; very few TORS patients require a tracheostomy or gastrostomy tube, and TORS patients experience lower rates of fistula formation. 22, 23 Investigators at the Mount Sinai School of Medicine in New York City studied TORS outcomes in 30 head and neck cancer patients; 25 of them (83%) also received adjuvant radiotherapy, and 11 (37%) received adjuvant CRT. 24 The researchers reported an 18-month disease-free survival rate of 78% and an overall survival rate of 90%. They also compared these patients with a stage-matched cohort of patients who were treated with definitive CRT alone. They found that the primary surgery patients had a better swallowing profile and oral diet tolerance, as measured by return-to-baseline metrics at 9 and 12 months after treatment according to Performance Status Scale for Head and Neck Patients scores and Functional Oral Intake scores.
While subject to the biases inherent in patient selection and limited follow-up, the emerging data are interesting in that they refute the commonly held belief that eliminating surgery from the definitive management of advanced oropharyngeal cancer patients should minimize long-term swallowing and speech morbidity. How the rapid evolution of minimally invasive surgical techniques and subsequent reductions in morbidity affects future practice patterns for patients with HPV-negative oropharyngeal cancer remains to be seen.
To the best of our knowledge, a trial comparing the efficacy and toxicity of primary surgery with that of radiotherapy has never been conducted in patients with oropharyngeal cancer. While our data suggest that no survival difference exists among HPV-negative oropharyngeal cancer patients treated with either modality, considerations regarding toxicity and function are increasingly relevant. This is particularly the case given the advent of TORS, which has been heralded as a less invasive technique than open surgery. For instance, several studies have shown better long-term swallowing outcomes with TORS than with CRT regarding Rash, Daly, DuRbin-Johnson, Vaughan, Chen patient-reported dysphagia and laryngoesophageal dysfunction. 25, 26 Our group recently conducted a retrospective matched-cohort analysis of 31 oropharyngeal cancer patients who were treated with either definitive CRT or with surgery (TORS or transoral CO 2 laser microsurgery) plus postoperative radiotherapy. 25 Notably, the incidence of esophageal stricture and enteral feeding tube dependence were both significantly higher in the CRT group. However, it must be recognized that selection bias is inherent in any retrospective comparison, and in our previous study we could not account for differences in chemotherapy use, radiotherapy treatment volumes, underlying comorbidities, and tumor resectability.
Given the inherent selection bias of retrospective comparisons, we need well-designed prospective trials that incorporate toxicity and quality-of-life endpoints to identify the optimal mode of treatment for patients with oropharyngeal cancer. Without randomized, prospective clinical data, the role of surgery in locally advanced oropharyngeal carcinoma continues to be speculative.
Although the use of surgery followed by radiotherapy logically represents a more aggressive approach and intuitively could improve outcomes, our study failed to demonstrate any advantage to the addition of surgery to RT for HPV-negative oropharyngeal cancer. In our series, the number of events was too small to detect any association between tumor size and locoregional control by treatment modality. However, patients with bulky T4 or N2b-3 disease who experienced locoregional failure were treated in equal proportions with primary surgery and definitive CRT.
The limitations of our study relate to its retrospective nature, limited sample size, and relatively short follow-up period. Also, we cannot discount the potential influence of patient selection in treatment decision making. For instance, it is likely that surgically treated patients tended to undergo rigorous preoperative evaluation and were generally in better health and had fewer medical comorbidities.
Other limitations relate to the lack of a central review of p16 specimens. While pathologists generally score tumors as positive based on the current standard of strong and diffuse nuclear and cytoplasmic staining, interobserver variability in the analysis and interpretation of p16 status is possible. Although p16 expression has been shown to be a reliable surrogate for tumor HPV status, it is not 100% accurate. 27 Given that the false-negative rate has been reported to range from 3 to 5%, the possibility that we inadvertently and unknowingly included patients with HPV-positive disease in our study must be considered. 28 In conclusion, our findings affirm the notion that regardless of treatment modality, HPV-negative squamous cell carcinomas of the oropharynx arising from long-term tobacco and/or alcohol exposure represent a more aggressive phenotype that is capable of evading cell death with current treatment options.
More recent work has revealed that within the HPV-negative subset, it may be possible to use biomarkers to stratify patients into risk groups that are amenable to treatment intensification, including targeted therapies or the use of hypoxia modifiers with concurrent CRT.
